ERBB2 and breast carcinoma: The next primary outcome, LAScd, was assessed in all aforementioned studies, as well as by Meloche et al. They conducted a prospective cohort analysis of 51 female patients (mean age 50.5 ± 9.8 years) with HER2+ breast cancer who underwent sequential AC treatment.